This identifies CD123 as an attractive target for antibody-based immunotherapy.6, 16 Indeed, our present results are in line with those data regarding the high expression of CD123 on bulk AML cells and the CD34+CD38− fraction, which typically contains LSCs. This evidence concerns the gene CD34 and acute myeloid leukemia.